SLC5A2 and Peritoneal Fibrosis: After demonstrating the ameliorating effects of SGLT2 inhibition on the development of peritoneal fibrosis, angiogenesis, and UF failure in a high-glucose milieu, we were interested to evaluate its effects on intraperitoneal inflammation.